ZYZymeworks Inc. ZYME · NASDAQ
$28.22 -0.77% (-$0.22)
- Market cap
- $1.83B
- Enterprise value
- -$161.6B
- P/E
- -
- Forward P/E
- 24.3x
- PEG
- -
- P/S
- 49.4x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -0.0%
- Gross margin
- 87.8%
- Net margin
- -404.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.17
- Free float
- 96.0%
About the company
Zymeworks Inc. (ZYME) is a Canadian biotechnology company specializing in the development of biologic drugs and therapies for oncological diseases and other serious conditions. With activities in biotechnology and pharmacology, Zymeworks Inc. is a key player in the world of innovative treatment approaches for various diseases. Their research focuses on discovering new biologic therapies and drugs that target specific biological mechanisms and pathways within the body. The company aims to provide modern and targeted treatment solutions that can bring new hope to patients with oncological and other serious diseases. Zymeworks Inc. is characterized by a high level of expertise in biotechnology and medicine. Zymeworks Inc. (ZYME) shares could be suitable for investors looking for an investment opportunity in the biotechnology sector with a company that specializes in innovative biologic treatment approaches and therapies for various serious conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Kenneth H. Galbraith
Employees
231
Headquarters
Middletown
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number